Cellular Reprogramming Tools - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511246490

Publication Date:

November 5, 2024

Pages:

115

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Cellular Reprogramming Tools was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Cellular Reprogramming Tools was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cellular Reprogramming Tools was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Cellular Reprogramming Tools was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Cellular Reprogramming Tools include Celgene, BIOTIME, Human Longevity, Advanced Cell Technology, Mesoblast, STEMCELL Technologies, Osiris Therapeutics, Cynata and Astellas Pharma, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cellular Reprogramming Tools, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cellular Reprogramming Tools by region & country, by Type, and by Application.
The Cellular Reprogramming Tools market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cellular Reprogramming Tools.
Market Segmentation
By Company
Celgene
BIOTIME
Human Longevity
Advanced Cell Technology
Mesoblast
STEMCELL Technologies
Osiris Therapeutics
Cynata
Astellas Pharma
FUJIFILM Holdings
EVOTEC
Japan Tissue Engineering
Segment by Type:
Adult Stem Cells
Human Embryonic Stem Cells
Induced Pluripotent Stem Cells
Other
Segment by Application
Drug Development
Regenerative Medicine
Toxicity Test
Academic Research
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cellular Reprogramming Tools manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cellular Reprogramming Tools in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cellular Reprogramming Tools in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Cellular Reprogramming Tools Product Introduction
1.2 Global Cellular Reprogramming Tools Market Size Forecast
1.3 Cellular Reprogramming Tools Market Trends & Drivers
1.3.1 Cellular Reprogramming Tools Industry Trends
1.3.2 Cellular Reprogramming Tools Market Drivers & Opportunity
1.3.3 Cellular Reprogramming Tools Market Challenges
1.3.4 Cellular Reprogramming Tools Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cellular Reprogramming Tools Players Revenue Ranking (2023)
2.2 Global Cellular Reprogramming Tools Revenue by Company (2019-2024)
2.3 Key Companies Cellular Reprogramming Tools Manufacturing Base Distribution and Headquarters
2.4 Key Companies Cellular Reprogramming Tools Product Offered
2.5 Key Companies Time to Begin Mass Production of Cellular Reprogramming Tools
2.6 Cellular Reprogramming Tools Market Competitive Analysis
2.6.1 Cellular Reprogramming Tools Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Cellular Reprogramming Tools Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cellular Reprogramming Tools as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Adult Stem Cells
3.1.2 Human Embryonic Stem Cells
3.1.3 Induced Pluripotent Stem Cells
3.1.4 Other
3.2 Global Cellular Reprogramming Tools Sales Value by Type
3.2.1 Global Cellular Reprogramming Tools Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cellular Reprogramming Tools Sales Value, by Type (2019-2030)
3.2.3 Global Cellular Reprogramming Tools Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Drug Development
4.1.2 Regenerative Medicine
4.1.3 Toxicity Test
4.1.4 Academic Research
4.1.5 Other
4.2 Global Cellular Reprogramming Tools Sales Value by Application
4.2.1 Global Cellular Reprogramming Tools Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cellular Reprogramming Tools Sales Value, by Application (2019-2030)
4.2.3 Global Cellular Reprogramming Tools Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Cellular Reprogramming Tools Sales Value by Region
5.1.1 Global Cellular Reprogramming Tools Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cellular Reprogramming Tools Sales Value by Region (2019-2024)
5.1.3 Global Cellular Reprogramming Tools Sales Value by Region (2025-2030)
5.1.4 Global Cellular Reprogramming Tools Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Cellular Reprogramming Tools Sales Value, 2019-2030
5.2.2 North America Cellular Reprogramming Tools Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Cellular Reprogramming Tools Sales Value, 2019-2030
5.3.2 Europe Cellular Reprogramming Tools Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Cellular Reprogramming Tools Sales Value, 2019-2030
5.4.2 Asia Pacific Cellular Reprogramming Tools Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Cellular Reprogramming Tools Sales Value, 2019-2030
5.5.2 South America Cellular Reprogramming Tools Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Cellular Reprogramming Tools Sales Value, 2019-2030
5.6.2 Middle East & Africa Cellular Reprogramming Tools Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cellular Reprogramming Tools Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cellular Reprogramming Tools Sales Value
6.3 United States
6.3.1 United States Cellular Reprogramming Tools Sales Value, 2019-2030
6.3.2 United States Cellular Reprogramming Tools Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cellular Reprogramming Tools Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cellular Reprogramming Tools Sales Value, 2019-2030
6.4.2 Europe Cellular Reprogramming Tools Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cellular Reprogramming Tools Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cellular Reprogramming Tools Sales Value, 2019-2030
6.5.2 China Cellular Reprogramming Tools Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cellular Reprogramming Tools Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cellular Reprogramming Tools Sales Value, 2019-2030
6.6.2 Japan Cellular Reprogramming Tools Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cellular Reprogramming Tools Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cellular Reprogramming Tools Sales Value, 2019-2030
6.7.2 South Korea Cellular Reprogramming Tools Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cellular Reprogramming Tools Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cellular Reprogramming Tools Sales Value, 2019-2030
6.8.2 Southeast Asia Cellular Reprogramming Tools Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cellular Reprogramming Tools Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cellular Reprogramming Tools Sales Value, 2019-2030
6.9.2 India Cellular Reprogramming Tools Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cellular Reprogramming Tools Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Celgene
7.1.1 Celgene Profile
7.1.2 Celgene Main Business
7.1.3 Celgene Cellular Reprogramming Tools Products, Services and Solutions
7.1.4 Celgene Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.1.5 Celgene Recent Developments
7.2 BIOTIME
7.2.1 BIOTIME Profile
7.2.2 BIOTIME Main Business
7.2.3 BIOTIME Cellular Reprogramming Tools Products, Services and Solutions
7.2.4 BIOTIME Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.2.5 BIOTIME Recent Developments
7.3 Human Longevity
7.3.1 Human Longevity Profile
7.3.2 Human Longevity Main Business
7.3.3 Human Longevity Cellular Reprogramming Tools Products, Services and Solutions
7.3.4 Human Longevity Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.3.5 Advanced Cell Technology Recent Developments
7.4 Advanced Cell Technology
7.4.1 Advanced Cell Technology Profile
7.4.2 Advanced Cell Technology Main Business
7.4.3 Advanced Cell Technology Cellular Reprogramming Tools Products, Services and Solutions
7.4.4 Advanced Cell Technology Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.4.5 Advanced Cell Technology Recent Developments
7.5 Mesoblast
7.5.1 Mesoblast Profile
7.5.2 Mesoblast Main Business
7.5.3 Mesoblast Cellular Reprogramming Tools Products, Services and Solutions
7.5.4 Mesoblast Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.5.5 Mesoblast Recent Developments
7.6 STEMCELL Technologies
7.6.1 STEMCELL Technologies Profile
7.6.2 STEMCELL Technologies Main Business
7.6.3 STEMCELL Technologies Cellular Reprogramming Tools Products, Services and Solutions
7.6.4 STEMCELL Technologies Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.6.5 STEMCELL Technologies Recent Developments
7.7 Osiris Therapeutics
7.7.1 Osiris Therapeutics Profile
7.7.2 Osiris Therapeutics Main Business
7.7.3 Osiris Therapeutics Cellular Reprogramming Tools Products, Services and Solutions
7.7.4 Osiris Therapeutics Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.7.5 Osiris Therapeutics Recent Developments
7.8 Cynata
7.8.1 Cynata Profile
7.8.2 Cynata Main Business
7.8.3 Cynata Cellular Reprogramming Tools Products, Services and Solutions
7.8.4 Cynata Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.8.5 Cynata Recent Developments
7.9 Astellas Pharma
7.9.1 Astellas Pharma Profile
7.9.2 Astellas Pharma Main Business
7.9.3 Astellas Pharma Cellular Reprogramming Tools Products, Services and Solutions
7.9.4 Astellas Pharma Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.9.5 Astellas Pharma Recent Developments
7.10 FUJIFILM Holdings
7.10.1 FUJIFILM Holdings Profile
7.10.2 FUJIFILM Holdings Main Business
7.10.3 FUJIFILM Holdings Cellular Reprogramming Tools Products, Services and Solutions
7.10.4 FUJIFILM Holdings Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.10.5 FUJIFILM Holdings Recent Developments
7.11 EVOTEC
7.11.1 EVOTEC Profile
7.11.2 EVOTEC Main Business
7.11.3 EVOTEC Cellular Reprogramming Tools Products, Services and Solutions
7.11.4 EVOTEC Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.11.5 EVOTEC Recent Developments
7.12 Japan Tissue Engineering
7.12.1 Japan Tissue Engineering Profile
7.12.2 Japan Tissue Engineering Main Business
7.12.3 Japan Tissue Engineering Cellular Reprogramming Tools Products, Services and Solutions
7.12.4 Japan Tissue Engineering Cellular Reprogramming Tools Revenue (US$ Million) & (2019-2024)
7.12.5 Japan Tissue Engineering Recent Developments
8 Industry Chain Analysis
8.1 Cellular Reprogramming Tools Industrial Chain
8.2 Cellular Reprogramming Tools Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cellular Reprogramming Tools Sales Model
8.5.2 Sales Channel
8.5.3 Cellular Reprogramming Tools Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Celgene
BIOTIME
Human Longevity
Advanced Cell Technology
Mesoblast
STEMCELL Technologies
Osiris Therapeutics
Cynata
Astellas Pharma
FUJIFILM Holdings
EVOTEC
Japan Tissue Engineering

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂